Page last updated: 2024-11-13
mrk-409
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
MRK-409: GABA-A Receptor Agonists; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 22609888 |
| CHEMBL ID | 4303594 |
| SCHEMBL ID | 2656796 |
| MeSH ID | M0555237 |
Synonyms (29)
| Synonym |
|---|
| mk-0343 |
| mk 0343 |
| SCHEMBL2656796 |
| 7-cyclobutyl-3-(2,6-difluorophenyl)-6-[(1-methyl-1h-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazo[4,3-b]pyridazine |
| 9vse02330i , |
| 1,2,4-triazolo(4,3-b)pyridazine, 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)- |
| unii-9vse02330i |
| mrk-409 |
| 233275-76-8 |
| AKOS024458148 |
| mk-0343, >=98% (hplc) |
| NCGC00379122-01 |
| HY-101869 |
| CS-0022104 |
| DB13993 |
| AS-48283 |
| mfcd22683821 |
| 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine |
| DTXSID101016659 |
| mrk 409 |
| CHEMBL4303594 , |
| Q27273286 |
| 1,2,4-triazolo[4,3-b]pyridazine, 7-cyclobutyl-3-(2,6-difluorophenyl)-6-[(1-methyl-1h-1,2,4-triazol-5-yl)methoxy] |
| A912681 |
| 7-cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine |
| F30160 |
| mk0343 |
| bdbm50526870 |
| cid 22609888 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (11)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 16.9330 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 6.7412 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 6.7412 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 6.7412 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 6.7412 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 6.7412 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | Ki | 0.0002 | 0.0000 | 0.2108 | 5.6234 | AID1604538 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | Ki | 0.0002 | 0.0000 | 0.1881 | 9.0000 | AID1604538; AID1604540; AID1604541 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | Ki | 0.0002 | 0.0001 | 0.2076 | 9.0000 | AID1604538; AID1604540; AID1604541 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | Ki | 0.0002 | 0.0001 | 0.2442 | 5.6234 | AID1604541 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | Ki | 0.0002 | 0.0001 | 0.2515 | 5.6234 | AID1604540 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (63)
Molecular Functions (29)
Ceullar Components (37)
Bioassays (17)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1604541 | Displacement of [3H]-flumazenil from human GABAA alpha5beta3gamma2 expressed in Ltk cells | |||
| AID1604539 | Displacement of [3H]-flumazenil from human GABAA alpha2beta3gamma2 expressed in Ltk cells | |||
| AID1604540 | Displacement of [3H]-flumazenil from human GABAA alpha3beta3gamma2 expressed in Ltk cells | |||
| AID1553916 | Displacement of [3H]Ro-15-1788 from human GABA alpha2/beta2/gamma2 receptor expressed in HEK cell membranes measured after 2 hrs by topcount method | 2019 | Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12 | Design and Identification of a Novel, Functionally Subtype Selective GABA |
| AID1604544 | Positive allosteric modulation of recombinant human GABAA alpha3beta3gamma2 expressed in Ltk cells assessed as chlordiazepoxide-induced current response by whole cell patch clamp method relative to chlordiazepoxide | |||
| AID1604538 | Displacement of [3H]-flumazenil from human GABAA alpha1beta3gamma2 expressed in Ltk cells | |||
| AID1553918 | Positive allosteric modulation of human GABAA alpha1/beta3/gamma2 expressed in HEK293 cells assessed as increase in GABA-stimulated chloride current response at 100 times Ki measured after 15 secs by QPatch electrophysiology method relative to GABA | 2019 | Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12 | Design and Identification of a Novel, Functionally Subtype Selective GABA |
| AID1604568 | In vivo receptor occupancy at GABAA receptor in po dosed Sprague-Dawley rat assessed as brain concentration causing 50% reduction in [3H]-flumazenil receptor labeling by scintillation counting method | |||
| AID1553919 | Positive allosteric modulation of human GABAA alpha2/beta2/gamma2 expressed in HEK293 cells assessed as increase in GABA-stimulated chloride current response at 100 times Ki measured after 15 secs by QPatch electrophysiology method relative to GABA | 2019 | Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12 | Design and Identification of a Novel, Functionally Subtype Selective GABA |
| AID1604545 | Positive allosteric modulation of recombinant human GABAA alpha5beta3gamma2 expressed in Ltk cells assessed as chlordiazepoxide-induced current response by whole cell patch clamp method relative to chlordiazepoxide | |||
| AID1604543 | Positive allosteric modulation of recombinant human GABAA alpha2beta3gamma2 expressed in Ltk cells assessed as chlordiazepoxide-induced current response by whole cell patch clamp method relative to chlordiazepoxide | |||
| AID1604542 | Positive allosteric modulation of recombinant human GABAA alpha1beta3gamma2 expressed in Ltk cells assessed as chlordiazepoxide-induced current response by whole cell patch clamp method relative to chlordiazepoxide | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.20) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||